Composition comprising a cell death marker and a wavelength-optimized label
AssigneeUCL Business PLLC
InventorsFrancesca Cordeiro, Stephen Moss, Frederick Fitzke
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with a wavelength-optimised label and a method for monitoring cell death in the eye using a cell death marker labelled with a wavelength-optimised label.
Claims24
A method for identifying cell death in the eye, comprising providing a composition comprising a cell death marker labeled with a wavelength-optimized label, wherein the cell death marker is an annexin and the wavelength-optimized label is Dy-776 having the structure:
- or
- Dy-781 having the structure:
A method for monitoring cell death in the eye, comprising the steps of:
- (a) administering a composition comprising a cell death marker labeled with a wavelength-optimized label to a subject, wherein the cell death marker is an annexin and the wavelength-optimized label is Dy-776 having the structure:
- or Dy-781 having the structure:
- (b) generating an image of emission wavelength from the subject's eye using an imaging device;
- wherein the image is a representation of cell death in the eye.
A composition comprising a cell death marker labeled with a wavelength-optimized label, wherein the cell death marker is an annexin and the wavelength-optimized label is Dy-776 having the structure:
- or
- Dy-781 having the structure:
Dependencies are inferred from the claim text.